Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Acquisitions & Divestments (2016 - 2022)

Catalyst Pharmaceuticals (CPRX) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $9.9 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Change in Acquisitions & Divestments changed N/A year-over-year to $9.9 million, compared with a TTM value of $9.9 million through Dec 2022, changed N/A, and an annual FY2022 reading of $19.2 million, changed N/A over the prior year.
  • Change in Acquisitions & Divestments was $9.9 million for Q3 2022 at Catalyst Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $31.7 million in Q4 2019 and bottomed at $5.0 million in Q1 2020.
  • Average Change in Acquisitions & Divestments over 4 years is $14.4 million, with a median of $10.0 million recorded in 2019.
  • The sharpest move saw Change in Acquisitions & Divestments surged 122.95% in 2019, then crashed 75.49% in 2020.
  • Year by year, Change in Acquisitions & Divestments stood at $14.2 million in 2018, then soared by 122.95% to $31.7 million in 2019, then crashed by 84.21% to $5.0 million in 2020, then skyrocketed by 97.36% to $9.9 million in 2022.
  • Business Quant data shows Change in Acquisitions & Divestments for CPRX at $9.9 million in Q3 2022, $5.0 million in Q1 2020, and $31.7 million in Q4 2019.